Clinical Trials

Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors, Disease Progression

NCT02031536 2023-06-29

Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery

2 enrolled 8 charts

Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

NCT02687958 2023-05-30

Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin

30 enrolled

Carcinoma, Neuroendocrine

NCT02205515 2022-08-19

EBRT

Phase 1/2 Completed

17 enrolled

Carcinoma, Neuroendocrine

NCT01218555 2022-01-27

Study of Everolimus (RAD001) in Combination With Lenalidomide

EndocrineGenitourinaryNET

44 enrolled 9 charts

Kidney Neoplasms, Neuroendocrine Tumors

NCT01263951 2021-10-26

Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone

35 enrolled

EndocrineHead & Neck

Differentiated Thyroid Cancer

NCT01524783 2021-08-05

RADIANT-4

Phase 3 Completed

302 enrolled 16 charts

Neuroendocrine Tumors

NCT01789281 2021-06-11

Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.

Phase 4 Completed

34 enrolled 8 charts

Carcinoid Tumor, Neoplasms, Neuroendocrine Tumors

NCT02695459 2021-04-20

Cisplatinum and Everolimus in Patients With Metastatic or Unresectable NEC of Extrapulmonary Origin

39 enrolled

Carcinoma, Neuroendocrine

NCT01563354 2021-04-02

LUNA

124 enrolled 18 charts

Carcinoma, Neuroendocrine

NCT01263353 2020-12-21

COOPERATE-1

36 enrolled

Carcinoid Tumor

NCT02113800 2020-10-28

EVINEC

40 enrolled

EndocrineLymphoidNET

Lymphoma, Follicular, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT02315625 2020-09-09

Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery

16 enrolled 15 charts

Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT02248012 2019-12-19

Everolimus and Temozolomide in Advanced Gastroenteropancreatic Neuroendocrine Carcinoma (G3)

38 enrolled

Carcinoma, Neuroendocrine

NCT03014297 2019-08-08

Fosbretabulin With Everolimus in Neuroendocrine Tumors With Progression

Phase 1 Terminated

17 enrolled

EndocrineGenitourinaryNETThoracic

Neuroendocrine Tumors

NCT01115803 2019-02-05

A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors

Phase 1 Terminated

29 enrolled 19 charts

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Neoplasm Metastasis, Neuroendocrine Tumors

NCT00688623 2019-01-25

RAMSETE/CDE16

73 enrolled 13 charts

Carcinoid Tumor, Carcinoma, Neuroendocrine Tumors

NCT01595009 2018-11-29

An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1)

Phase 4 Completed

246 enrolled 16 charts

Neuroendocrine Tumors

NCT02305810 2018-11-07

A Biological Prospective Study in Patients With Metastatic Pancreatic NETs Treated With Everolimus

EndocrineGastrointestinal

54 enrolled

Pancreatic Neuroendocrine Tumour Metastatic

NCT01469572 2018-10-18

Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases

EndocrineGastrointestinalNET

13 enrolled

Liver Neoplasms, Neuroendocrine Tumors

NCT03629847 2018-08-14

Treatment of Neuroendocrine Tumors (NETs) With Combination of Everolimus and Radiolabeled Somatostatin Analogue

Phase 1/2 Unknown

30 enrolled

Metatropic dwarfism, Neuroendocrine Tumors

NCT01508104 2017-08-23

Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors

Phase 1 Terminated

19 enrolled

CNSEndocrineNET

Brain Neoplasms, Glioblastoma, Neoplasms, Neuroendocrine Tumors

NCT01374451 2016-12-20

COOPERATE-2

160 enrolled 17 charts

Adenoma, Islet Cell, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

NCT00804336 2016-10-19

Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors

22 enrolled

Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT01204476 2016-07-15

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

27 enrolled

CNSDermatologicEndocrine

Glucagonoma, Insulinoma, Paraganglioma, Somatostatinoma, Zollinger-Ellison Syndrome, Carcinoma, Merkel Cell, Carcinoma, Medullary

NCT01628913 2016-04-07

Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors

62 enrolled 7 charts

Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

NCT01152827 2015-05-20

PheoCarcRAD001

33 enrolled

CNSEndocrine

Paraganglioma, Extra-Adrenal, Pheochromocytoma

NCT01324492 2014-12-30

\MACS1304

16 enrolled

Lung Neuroendocrine Neoplasm

NCT01164176 2014-12-02

Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer

40 enrolled

EndocrineHead & Neck

Thyroid Cancer, Papillary, Head and Neck Neoplasms, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary, Thyroid Carcinoma, Anaplastic

NCT00412061 2014-11-21

RADIANT-2

Phase 3 Completed

429 enrolled 13 charts

EndocrineGastrointestinalNET

Carcinoid Tumor, Carcinoma, Malignant Carcinoid Syndrome, Neoplasms

NCT01864070 2014-07-22

Phase 1 TheraSphere + Everolimus With Neuroendocrine Tumors (NETs) + Liver Only or Liver Dominant Disease

Phase 1 Withdrawn

Liver Neoplasms, Neuroendocrine Tumors

NCT01118065 2013-08-12

Everolimus in Treating Patients With Progressive or Recurrent, Unresectable, or Metastatic Thyroid Cancer